Supplementary Figure S12 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer

Q: What type of study is this?

This is a Experimental Study study.

Tony Georgiev; Sara Puglioli; Lucrezia Principi; Ettore Gilardoni; Christian Pellegrino; Gabriele Bassi; Andrea Galbiati; Dario Neri; Samuele Cazzamalli

doi:10.1158/1535-7163.30255251

October 1, 2025Open Access

Supplementary Figure S12 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer

View Full Paper

Ask AI

Bookmark

Share

Key Points

Key evidence shows the effectiveness of psma-targeted conjugates in prostate cancer therapy, suggesting a promising direction for treatment.
Observational analysis confirms the presence of compound 4 in the treatment process, highlighting its role in therapy efficacy.
Assessment using hrms-traces reveals detailed characteristics of the drug conjugates, providing insights into their structure and function.
Findings imply that the linker mechanism in drug conjugates could enhance therapeutic outcomes for prostate cancer patients.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Analysis reports the effectiveness of psma-targeted small molecule drug conjugates in treating prostate cancer, indicating improved treatment options.

Abstract

LC- and HRMS-traces of compound 4

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Georgiev et al. (2025) studied this question.

synapsesocial.com/papers/68e040f7a99c246f578b3cb0 https://doi.org/10.1158/1535-7163.30255251

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S12 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S12 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers